VAXIRA
Vaxira® is an immunotherapeutic agent whose formula consists of the anti-idiotype monoclonal antibody Racotumomab and aluminum hydroxide (HA), a widely used adjuvant. HA improves the production of antibodies, but it is neither immunogenic nor a hapten. It behaves like "depot" at the injection site, from which the antigen is released slowly, and induces the formation of granulomas that attract immunocompetent cells, such as plasma cells that produce antibodies. HA can directly stimulate monocytes to produce proinflammatory cytokines that can activate T cells and possibly stimulate B cell responses.
VAXIRA
Industry:
Biotechnology Therapeutics
Website Url:
http://www.vaxira.com
Status:
Active
Contact:
0800 999 2495
Email Addresses:
[email protected]
Technology used in webpage:
British Virgin Island Server Location
Similar Organizations
Fast BioPharma
Fast BioPharma Ltd. develops therapeutic products for treatment of cancer.
LINDIS Biotech
LINDIS Biotech is to develop ektomun®, an innovative immunotherapeutic for the treatment of small cell lung cancer, melanoma.
Theobald Therapeutics LLC
Therapeutics including or based on genetically engineered bacteria
Migra Therapeutics
Migra Therapeutics is developing nanotechnology therapies for cancer.
Prosensa
Prosensa provides RNA-based therapeutics for the treatment of genetic disorders, infections and cancers.
Official Site Inspections
http://www.vaxira.com
- Host name: 199.59.243.228
- IP address: 199.59.243.228
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Vaxira"
Racotumomab - Wikipedia
Racotumomab (trade name Vaxira) is a therapeutic cancer vaccine for the treatment of solid tumors that is currently under clinical development by ReComBio (R and Research in Computational Biology), an international public-private consortium with the participation of the Center of Molecular Immunology at … See moreSee details»
Racotumomab (Vaxira) | HemOnc.org - A Hematology Oncology …
From Wikipedia: Racotumomab is an anti-idiotypic mouse monoclonal antibody that mimics NGc gangliosides, thus triggering an immune response against the tumor antigen NGcGM3. …See details»
Vaxira - Crunchbase Company Profile & Funding
Vaxira® is an immunotherapeutic agent whose formula consists of the anti-idiotype monoclonal antibody Racotumomab and aluminum hydroxide (HA), a widely used adjuvant. HA improves …See details»
Racotumomab - an overview | ScienceDirect Topics
Racotumomab (Vaxira) is an anti-idiotype vaccine that induces an immune response against the TAA neu-glycolyl containing gangliosides. A Phase II study demonstrated a longer median …See details»
Racotumomab - a novel anti-idiotype monoclonal antibody
It is adjuvanted with aluminum hydroxide for intradermal administration as a cancer vaccine (racotumomab-Alum, known commercially as Vaxira®). Racotumomab is currently being …See details»
Vaxira Company Profile - Office Locations, Competitors, Revenue …
Vaxira (also known as Racotumomab) is a company that provides a therapeutic vaccine for the treatment of non-small cell lung cancer (NSCLC). It is composed of Racotumomab and …See details»
Immunotherapy for non-small cell lung cancer (NSCLC
Aug 1, 2021 · In 2013, Racotumomab-alum was launched as Vaxira® by CIMAB in Cuba and Argentina as a therapeutic treatment for advanced-stage NSCLC for patients who were …See details»
A 'vaccine' for lung cancer? - ZDNET
Jun 28, 2013 · In the case of Vaxira, the Cuban investigators identified a compound called an antigen present in the cell walls of non-small cell lung cancer tumors and, along with the …See details»
Insights into the role of sialylation in cancer progression and ...
Nov 4, 2020 · Following a different approach, Racotumomab (trade name Vaxira) is a therapeutic vaccine that triggers an immune response against the tumour antigen N-glycolyl GM3 …See details»
Vaxira as adjuvant treatment for non-small cell lung cancer
Open randomized controlled clinical trial in patients with non-small cell lung cancer, stage IB, II and IIIA, treated or not with VAXIRA®, after surgery and adjuvant cisplatin-based chemotherapySee details»
Therapeutic vaccines for advanced non‐small cell lung cancer
Aug 1, 2019 · To evaluate the effectiveness and safety of therapeutic vaccines for people with advanced non‐small cell lung cancer (non‐irradiatable stage IIIB and stage IV NSCLC) who …See details»
Differential effects of two therapeutic cancer vaccines on short
Jan 1, 2018 · Data from two randomized, multicenter, controlled clinical trials was used to evaluate the effect of two therapeutic vaccines (anti-idiotypic vaccine VAXIRA and anti-EGF …See details»
A Randomized, Multicenter, Placebo-Controlled Clinical Trial of ...
Jul 14, 2014 · Here, we present the clinical and immunologic results from a randomized study of racotumomab-alum vaccine, targeting NeuGcGM3 ganglioside, as switch maintenance …See details»
#innovate4health Latin American research collaboration creates …
Nov 1, 2018 · Hope is at hand thanks to the world’s first lung cancer vaccine, Vaxira, developed by a consortium of Argentinean and Cuban universities, companies and research institutes. A …See details»
Differential effects of two therapeutic cancer vaccines on short
Methods: Data from two randomized, multicenter, controlled clinical trials was used to evaluate the effect of two therapeutic vaccines (anti-idiotypic vaccine VAXIRA and anti-EGF vaccine …See details»
Frontiers | CIMAvax-EGF: A New Therapeutic Vaccine for Advanced …
Mar 12, 2017 · CIMAvax-EGF vaccine consists of a chemical conjugate of the EGF with the P64 protein derived from the Meningitis B bacteria and Montanide ISA 51, as adjuvant. The …See details»
VACSERA proceeds to localize pharmaceutical industry in Egypt as …
Jul 13, 2022 · The Vacsera factory complex, located in October city, is scheduled to produce 400 million doses of veterinary vaccines for bird flu, in addition to 7 other vaccines related to …See details»
Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in ...
Background: CIMAvax-EGF is a novel growth-factor depleting immunotherapy consisting of human recombinant EGF conjugated to recombinant P64k derived from Neisseria …See details»
P2.34: Vaxira and CIMAvax-EGF Therapeutic Vaccines Combination …
The main clinical and immunological results obtained with two different therapeutic vaccines used in advanced non-small-cell lung cancer patients, inducing an immune response against …See details»
Liquid Nitrogen & Balloon Experiment | Museum of Science
Jun 28, 2024 · What happens when you put balloons in liquid nitrogen? In this educational video, Museum Educator Kate demonstrates the physics of this super cold science experiment.See details»